| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Case Report on Primary Gastro-Intestinal Aspergilloma with Abdominal Wall Invasion
|
Hadchiti, Marie-Therezia
|
|
2015
|
15 |
S |
p. S200-
1 p.
|
artikel
|
| 2 |
Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
|
Jaglowski, Samantha M.
|
|
2015
|
15 |
S |
p. S206-S207
2 p.
|
artikel
|
| 3 |
Acute Myeloid Leukemia with t(v;5q33-34) Does Not Always have Myelodysplastic Features but is Associated with Poor Outcome
|
Yabe, Mariko
|
|
2015
|
15 |
S |
p. S187-S188
2 p.
|
artikel
|
| 4 |
Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features
|
Yabe, Mariko
|
|
2015
|
15 |
S |
p. S85-S90
6 p.
|
artikel
|
| 5 |
Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program
|
Shen, Qi
|
|
2015
|
15 |
S |
p. S220-S221
2 p.
|
artikel
|
| 6 |
Allogeneic Stem Cell Transplantation In Patients With Acute Myeloid Leukemia: a report from the Austrian Stem Cell Transplantation Registry (ASCTR)
|
Böhm, A.
|
|
2015
|
15 |
S |
p. S183-
1 p.
|
artikel
|
| 7 |
Allogeneic Stem Cell Transplant in AML with Adverse Cytogenetics
|
Hossain, Nasheed
|
|
2015
|
15 |
S |
p. S200-
1 p.
|
artikel
|
| 8 |
Allogeneic Transplantation for Unfavorable-Risk Acute Myeloid Leukemia
|
Fernandez, Hugo F.
|
|
2015
|
15 |
S |
p. S70-S72
3 p.
|
artikel
|
| 9 |
Allogenic Stem Cell Transplant in Patients with Germline GATA2 Mutation
|
Kochuparambil, Samith T.
|
|
2015
|
15 |
S |
p. S188-S189
2 p.
|
artikel
|
| 10 |
Analysis of Prognostic Factors in Patients with HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas
|
Mathew, Blessy
|
|
2015
|
15 |
S |
p. S230-
1 p.
|
artikel
|
| 11 |
A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML)
|
Nazha, Aziz
|
|
2015
|
15 |
S |
p. S195-S196
2 p.
|
artikel
|
| 12 |
A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy
|
Rosenthal, Allison
|
|
2015
|
15 |
S |
p. S225-S226
2 p.
|
artikel
|
| 13 |
A retrospective study of the allogeneic hematopoietic stem cell transplantation in Ph+ leukemia patients: the 25 years’ experience of Gustave Roussy Cancer Center
|
Chamseddine, A.N.
|
|
2015
|
15 |
S |
p. S210-S211
2 p.
|
artikel
|
| 14 |
Assessment of molecular markers in AML patients: A hospital-based study in Lebanon
|
El Halabi, Layal
|
|
2015
|
15 |
S |
p. S197-
1 p.
|
artikel
|
| 15 |
Assessment of Molecular Markers in AML Patients: A Hospital-Based Study in Lebanon
|
El Halabi, Layal
|
|
2015
|
15 |
S |
p. S80-S84
5 p.
|
artikel
|
| 16 |
Association of lymphoma/myeloma and Philadelphia-chromosome negative myeloproliferative neoplasms: clinical characteristics, therapy and outcome
|
George, Binsah
|
|
2015
|
15 |
S |
p. S236-
1 p.
|
artikel
|
| 17 |
ASXL1 and SETBP1 Mutations and Their Prognostic Contribution in Chronic Myelomonocytic Leukemia: An International Study of 466 Patients
|
Patnaik, Mrinal M.
|
|
2015
|
15 |
S |
p. S234-
1 p.
|
artikel
|
| 18 |
ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?
|
Hsu, Jingmei
|
|
2015
|
15 |
S |
p. S195-
1 p.
|
artikel
|
| 19 |
A third of transfusion-dependent patients with myelodysplastic syndromes (MDS) develop alloantibodies against red blood cell antigens
|
Rozovski, Uri
|
|
2015
|
15 |
S |
p. S231-
1 p.
|
artikel
|
| 20 |
BL-8040, a CXCR4 antagonist, synergizes with the FLT3 inhibitor AC220 inducing apoptosis and reducing minimal residual disease to prolong survival of AML diseased mice
|
Pereg, Yaron
|
|
2015
|
15 |
S |
p. S179-
1 p.
|
artikel
|
| 21 |
Bleeding Diathesis Associated with Acquired von Willebrand Syndrome in Three Patients with Chronic Lymphocytic Leukemia
|
Vitale, Candida
|
|
2015
|
15 |
S |
p. S201-
1 p.
|
artikel
|
| 22 |
Brentuximab Vedotin in refractory or relapsed Peripheral T-cell Lymphoma: The French name patient program experience in 66 patients
|
Lamarque, Mathilde
|
|
2015
|
15 |
S |
p. S221-S222
2 p.
|
artikel
|
| 23 |
Cardiovascular Adverse Events Associated with Ibrutinib in Chronic Lymphocytic Leukemia Patients
|
George, Binsah
|
|
2015
|
15 |
S |
p. S208-
1 p.
|
artikel
|
| 24 |
Central Nervous System Involvement in T-cell Lymphoma: A Single Center Experience
|
Mehta, Neha
|
|
2015
|
15 |
S |
p. S229-
1 p.
|
artikel
|
| 25 |
Characteristics of therapy-related myeloid neoplasms in breast cancer patients
|
Sevcikova, Katarina
|
|
2015
|
15 |
S |
p. S186-S187
2 p.
|
artikel
|
| 26 |
Characterization of new cryptic rearrangements of the erythropoietin receptor in Ph-like acute lymphoblastic leukemia
|
Iacobucci, Ilaria
|
|
2015
|
15 |
S |
p. S175-S176
2 p.
|
artikel
|
| 27 |
Chromosomal 3 Abnormalities in Myelodysplastic Syndromes: Implications on Prognosis and Response to Treatment
|
Sallman, David
|
|
2015
|
15 |
S |
p. S232-
1 p.
|
artikel
|
| 28 |
Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program
|
Ye, Qinng
|
|
2015
|
15 |
S |
p. S228-
1 p.
|
artikel
|
| 29 |
Clinical description of acute promyelocytic leukemia (APL) patients receiving all-trans retinoic acid (ATRA) who develop pseudotumor cerebri: Incidence, diagnosis, outcomes, and recommendations for management
|
Coombs, Catherine C.
|
|
2015
|
15 |
S |
p. S194-
1 p.
|
artikel
|
| 30 |
Continuing Medical Education Post-Test [Course Code: E112406]
|
|
|
2015
|
15 |
S |
p. S242-S245
4 p.
|
artikel
|
| 31 |
Copy Number Alterations in patients with mature B (Burkitt-type) acute lymphoblastic leukaemia treated with specific immunochemotherapy
|
Genescà, Eulàlia
|
|
2015
|
15 |
S |
p. S174-
1 p.
|
artikel
|
| 32 |
Cost of treatment failure in patients with mantle cell lymphoma: results of a large U.S. observational study
|
Senbetta, Mekre
|
|
2015
|
15 |
S |
p. S218-
1 p.
|
artikel
|
| 33 |
CYC065, potential therapeutic agent for AML and MLL leukaemia
|
Frame, Sheelagh
|
|
2015
|
15 |
S |
p. S183-
1 p.
|
artikel
|
| 34 |
Cytochrome P450 and drug metabolism in the stem cell niche
|
Alonso, Salvador
|
|
2015
|
15 |
S |
p. S178-
1 p.
|
artikel
|
| 35 |
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia
|
Muppidi, Monica R.
|
|
2015
|
15 |
S |
p. S73-S79
7 p.
|
artikel
|
| 36 |
Decitabine and sorafenib therapy in FLT3-ITD mutant acute myeloid leukemia- A case series
|
Muppidi, Monica R.
|
|
2015
|
15 |
S |
p. S187-
1 p.
|
artikel
|
| 37 |
Decitabine enhances the expression of TAP1 facilitating antigen-specific immune responses in acute myeloid leukemia
|
Paluch, Benjamin
|
|
2015
|
15 |
S |
p. S190-S191
2 p.
|
artikel
|
| 38 |
Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts
|
Kadia, Tapan
|
|
2015
|
15 |
S |
p. S192-
1 p.
|
artikel
|
| 39 |
Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients
|
Kumar, Anita
|
|
2015
|
15 |
S |
p. S176-S177
2 p.
|
artikel
|
| 40 |
Detection of JAK2 V617F mutation, secondary to the presence of BCR-ABL1 translocation in a patient with chronic myeloid leukemia: report of a case and review of the literature
|
Carranza, Claudia
|
|
2015
|
15 |
S |
p. S213-
1 p.
|
artikel
|
| 41 |
Detection of Minimal Residual Disease Using Next Generation Sequencing for Antigen Receptor Gene Rearrangements in Acute Lymphoblastic Leukemia
|
Liang, Der-Cherng
|
|
2015
|
15 |
S |
p. S172-
1 p.
|
artikel
|
| 42 |
Development of a novel humanized anti-CD20 chimeric antigen receptor; Effect on the CD20 down-regulated and mAb therapy resistant tumor cells
|
Watanabe, Keisuke
|
|
2015
|
15 |
S |
p. S217-
1 p.
|
artikel
|
| 43 |
Development of a sensitive, quantitative multiplex BCR-ABL1 assay aligned directly to the who primary standard reference materials to report expression on the International Scale
|
Laosinchai-Wolf, Walairat
|
|
2015
|
15 |
S |
p. S212-S213
2 p.
|
artikel
|
| 44 |
Diffuse Large B-Cell Lymphoma in adults aged 65 years and older: A retrospective multicenter analysis of clinical characteristics and therapeutic outcomes
|
Dogu, Mehmet Hilmi
|
|
2015
|
15 |
S |
p. S218-
1 p.
|
artikel
|
| 45 |
Disseminated Intra-Abdominal Aspergilloma With Abdominal Wall Invasion in a Patient With Acute Myeloid Leukemia: A Case Report
|
Hadchiti, Marie-Therezia
|
|
2015
|
15 |
S |
p. S94-S97
4 p.
|
artikel
|
| 46 |
Distinguishing the Causes of Pulmonary Infiltrates in Patients With Acute Leukemia
|
Nucci, Marcio
|
|
2015
|
15 |
S |
p. S98-S103
6 p.
|
artikel
|
| 47 |
DNMT3A mutations exert a dominant adverse effect in De novo acute myeloid leukemia with concurrent FLT3 and NPM1 mutations
|
Loghavi, Sanam
|
|
2015
|
15 |
S |
p. S188-
1 p.
|
artikel
|
| 48 |
Does transfusion of aged red blood cells lead to adverse outcomes in Acute Myeloid Leukemia patients undergoing Hematopoietic stem cell Transplantation?
|
Aung, Fleur
|
|
2015
|
15 |
S |
p. S179-
1 p.
|
artikel
|
| 49 |
Donor Derived Myelodysplastic Syndrome in a Pediatric Allogeneic Transplant Recipient
|
Gaikwad, Amos
|
|
2015
|
15 |
S |
p. S197-S198
2 p.
|
artikel
|
| 50 |
Drug induced depletion of myeloid progenitors in bone marrow samples as an ex vivo estimation of hematotoxicity
|
Primo, Daniel
|
|
2015
|
15 |
S |
p. S240-S241
2 p.
|
artikel
|
| 51 |
Editorial Board/Masthead
|
|
|
2015
|
15 |
S |
p. A5-
1 p.
|
artikel
|
| 52 |
Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study
|
Heiblig, Maël
|
|
2015
|
15 |
S |
p. S7-S13
7 p.
|
artikel
|
| 53 |
Elucidation of B cell receptor signaling in Burkitt’s lymphoma reveals novel signaling nodes with potential therapeutic relevance
|
Oellerich, T.
|
|
2015
|
15 |
S |
p. S226-S227
2 p.
|
artikel
|
| 54 |
EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients
|
Lipton, Jeffrey H.
|
|
2015
|
15 |
S |
p. S211-
1 p.
|
artikel
|
| 55 |
Epstein-Barr Virus-Positive Plasmacytoma in Immunocompetent Patients
|
Loghavi, Sanam
|
|
2015
|
15 |
S |
p. S216-S217
2 p.
|
artikel
|
| 56 |
Evaluating Packed Red Blood Cell (RBC) Product Utilization on Hematologic Malignancy Service (HMS): A Quality Improvement Initiative
|
Marks, Douglas
|
|
2015
|
15 |
S |
p. S199-S200
2 p.
|
artikel
|
| 57 |
Evaluation of JAK2 V617F mutation and BCR-ABL translocation status in the work-up of MPN: A hospital-based study in Lebanon
|
Saidy, G.
|
|
2015
|
15 |
S |
p. S237-
1 p.
|
artikel
|
| 58 |
Extramedullary involvement at diagnosis is a poor prognostic factor in patients with Waldenstrom macroglobulinemia: The MD Anderson Cancer Center experience
|
Cao, Xin
|
|
2015
|
15 |
S |
p. S229-
1 p.
|
artikel
|
| 59 |
EZH2-Activating Mutations in DLBCL Are Easily Predictable by Routine Immunohistochemistry Analysis: a Tool to More Efficiently Define EZH2 Inhibitor-Sensitive Patients?
|
Dubois, Sydney
|
|
2015
|
15 |
S |
p. S220-
1 p.
|
artikel
|
| 60 |
Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia
|
Chikkodi, Santosh V.
|
|
2015
|
15 |
S |
p. S114-S119
6 p.
|
artikel
|
| 61 |
First Report of NRAS Mutations Contributing to Donor Cell Leukemia after allogeneic Bone Marrow Transplantation for Severe Aplastic Anemia
|
Assi, Rita
|
|
2015
|
15 |
S |
p. S240-
1 p.
|
artikel
|
| 62 |
Frequency of the ETV6-RUNX1, BCR-ABL1, TCF3-PBX1 and MLL-AFF1 fusion genes in Guatemalan Pediatric Acute Lymphoblastic Leukemia Patients and Its Ethnic Associations
|
Carranza Meléndez, Claudia Lorena
|
|
2015
|
15 |
S |
p. S170-
1 p.
|
artikel
|
| 63 |
G-CSF Reduces ex vivo Acute Myeloid Leukemia Blasts Cells Viability in the Presence of Bone Marrow Stroma Cells
|
Nomdedeu, Meritxell
|
|
2015
|
15 |
S |
p. S189-S190
2 p.
|
artikel
|
| 64 |
Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings
|
Karol, Seth E.
|
|
2015
|
15 |
S |
p. S177-
1 p.
|
artikel
|
| 65 |
Hairy cell leukemia cell lines lack signature BRAF mutations of typical disease and MAP2K1 mutations of atypical disease
|
Weston-Bell, Nicola
|
|
2015
|
15 |
S |
p. S219-
1 p.
|
artikel
|
| 66 |
Hemophagocytic Lymphohistiocytosis (HLH) in Malignant Hematology: Uncommon but Should Not be Forgotten?
|
Roe, Christa
|
|
2015
|
15 |
S |
p. S227-
1 p.
|
artikel
|
| 67 |
Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten?
|
Roe, Christa
|
|
2015
|
15 |
S |
p. S147-S150
4 p.
|
artikel
|
| 68 |
Heterogeneous effects of targeting WNT signaling in AML blasts
|
Srivastava, Pragya
|
|
2015
|
15 |
S |
p. S185-
1 p.
|
artikel
|
| 69 |
High Pseudotumor Cerebri Incidence in Tretinoin and Arsenic Treated Acute Promyelocytic Leukemia and the Role of Topiramate After Acetazolamide Failure
|
Freyer, Craig
|
|
2015
|
15 |
S |
p. S199-
1 p.
|
artikel
|
| 70 |
High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial
|
Pritchard, Justin R.
|
|
2015
|
15 |
S |
p. S212-
1 p.
|
artikel
|
| 71 |
How We Treat Myeloproliferative Neoplasms
|
Harrison, Claire N.
|
|
2015
|
15 |
S |
p. S19-S26
8 p.
|
artikel
|
| 72 |
Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial
|
Brown, J. Jennifer R.
|
|
2015
|
15 |
S |
p. S204-
1 p.
|
artikel
|
| 73 |
Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control Subjects
|
Brito da Silva, Priscilla
|
|
2015
|
15 |
S |
p. S151-S157
7 p.
|
artikel
|
| 74 |
Impact of initial body mass index (BMI) on survival outcome of patients with acute leukemia (AL): myth or reality?
|
Heiblig, Maël
|
|
2015
|
15 |
S |
p. S171-S172
2 p.
|
artikel
|
| 75 |
Impact of the immunoglobulin heavy chain variable region mutational status in patients with low risk chronic lymphocytic leukemia
|
Gemmer, Jennifer
|
|
2015
|
15 |
S |
p. S205-
1 p.
|
artikel
|
| 76 |
Impact of Therapy-Related De Novo Acute Myeloid Leukemia on Response and Survival
|
Sasaki, Koji
|
|
2015
|
15 |
S |
p. S181-S182
2 p.
|
artikel
|
| 77 |
Impact of treatment on IL-4, IL-6, IL-10 and sCD25 levels in patients with Hodgkin’s Lymphoma
|
Silva, Priscilla Brito
|
|
2015
|
15 |
S |
p. S222-S223
2 p.
|
artikel
|
| 78 |
Incidence of and risk factors for acute myeloid leukemia involvement of the central nervous system
|
Rozovski, Uri
|
|
2015
|
15 |
S |
p. S180-
1 p.
|
artikel
|
| 79 |
Incidence Rate of Venous Thromboembolism (VTE) and Utilization of a VTE Prophylaxis Orderset Module In Hospitalized Patients With Leukemia
|
Ferrajoli, Alessandra
|
|
2015
|
15 |
S |
p. S184-S185
2 p.
|
artikel
|
| 80 |
Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
|
Jabbour, Elias
|
|
2015
|
15 |
S |
p. S171-
1 p.
|
artikel
|
| 81 |
Integrated Genomic Profiling, Therapy Response And Survival in Adult Acute Myelogenous Leukemia
|
Parkin, Brian
|
|
2015
|
15 |
S |
p. S193-
1 p.
|
artikel
|
| 82 |
Investigating the Role of JAK/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562
|
Dalgıç, Ceyda Tunakan
|
|
2015
|
15 |
S |
p. S161-S166
6 p.
|
artikel
|
| 83 |
Investigating The Role of JAK/STAT Pathway upon Dasatinib Induced Apoptosis for CML Cell Model K562
|
Tunakan Dalgiç, Ceyda
|
|
2015
|
15 |
S |
p. S209-S210
2 p.
|
artikel
|
| 84 |
Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis
|
El Fakih, Riad
|
|
2015
|
15 |
S |
p. S34-S42
9 p.
|
artikel
|
| 85 |
Large scale phophoproteomic analysis reveals that Wiskott-Aldrich syndrome protein regulates the oncogenic potential of anaplastic large cell lymphoma
|
Murga-Zamalloa, Carlos
|
|
2015
|
15 |
S |
p. S221-
1 p.
|
artikel
|
| 86 |
Long-term bone marrow stromal changes in patients with myelofibrosis treated with ruxolitinib
|
Kvasnicka, Hans Michael
|
|
2015
|
15 |
S |
p. S234-
1 p.
|
artikel
|
| 87 |
Long-Term Complete Responses to Combination Therapies and Allogenic Stem Cell Transplants in Sézary Patients
|
Polansky, Maxim
|
|
2015
|
15 |
S |
p. S227-S228
2 p.
|
artikel
|
| 88 |
Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
|
O’Brien, Susan M.
|
|
2015
|
15 |
S |
p. S206-
1 p.
|
artikel
|
| 89 |
Mantle Cell Lymphoma (MCL) Treatment Patterns, Healthcare Resource Use (HRU), and Costs in the United States
|
Kozma, Chris
|
|
2015
|
15 |
S |
p. S226-
1 p.
|
artikel
|
| 90 |
Measurement of the proliferation of clonal plasma cells by multiparametric flow cytometry is a clinically useful tool in relapsed multiple myeloma
|
Kochuparambil, Samith
|
|
2015
|
15 |
S |
p. S238-S239
2 p.
|
artikel
|
| 91 |
Mesenchymal Stem Cells Differentiate into Osteoblasts in the Presence of AML Cells through Up-regulation of RUNX2 and Induce Chemo-resistance
|
Battula, V. Lokesh
|
|
2015
|
15 |
S |
p. S185-S186
2 p.
|
artikel
|
| 92 |
Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?
|
Paietta, Elisabeth
|
|
2015
|
15 |
S |
p. S2-S6
5 p.
|
artikel
|
| 93 |
miR17 Suppresses Cell Proliferation in Zoledronic Acid Treated Chronic Myeloid Leukemia Cells by Inducing Autophagy
|
Caliskan, Cansu
|
|
2015
|
15 |
S |
p. S213-
1 p.
|
artikel
|
| 94 |
Molecular response assessment at 3 months time point is better in late chronic phase chronic myeloid leukemia patients
|
Malhotra, Pankaj
|
|
2015
|
15 |
S |
p. S214-
1 p.
|
artikel
|
| 95 |
Mutational Profiling of JAK2V617F vs. CALR mutated Primary Myelofibrosis
|
Santos, Fabio
|
|
2015
|
15 |
S |
p. S235-
1 p.
|
artikel
|
| 96 |
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
|
Soverini, Simona
|
|
2015
|
15 |
S |
p. S120-S128
9 p.
|
artikel
|
| 97 |
Mutations in the Toll-like receptor/MYD88 pathway in young (≤50 years) CLL patients
|
Martínez-Trillos, Alejandra
|
|
2015
|
15 |
S |
p. S203-
1 p.
|
artikel
|
| 98 |
MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma
|
Xu-Monette, Zijun Y.
|
|
2015
|
15 |
S |
p. S223-
1 p.
|
artikel
|
| 99 |
New Therapeutic Approaches in Polycythemia Vera
|
Falchi, Lorenzo
|
|
2015
|
15 |
S |
p. S27-S33
7 p.
|
artikel
|
| 100 |
Next generation sequencing-based monitoring for minimal residual disease in acute myeloid leukemia
|
Ok, Chi Young
|
|
2015
|
15 |
S |
p. S196-
1 p.
|
artikel
|
| 101 |
Normalization of B2-microglobulin During the First Year of Treatment is Predictive for Prolonged Progression-free and Overall Survival in CLL Treated with FCR or Ibrutinib-based Regimens
|
Thompson, Philip A.
|
|
2015
|
15 |
S |
p. S209-
1 p.
|
artikel
|
| 102 |
Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014
|
Feldman, Eric J.
|
|
2015
|
15 |
S |
p. S91-S93
3 p.
|
artikel
|
| 103 |
Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium
|
Li, Ling
|
|
2015
|
15 |
S |
p. S224-
1 p.
|
artikel
|
| 104 |
Ocular Adnexal Lymphomas: Experience of Single Center
|
Özkan, Melda Cömert
|
|
2015
|
15 |
S |
p. S217-
1 p.
|
artikel
|
| 105 |
Ocular Adnexal Lymphomas: Single-Center Experience
|
Özkan, Melda Cömert
|
|
2015
|
15 |
S |
p. S158-S160
3 p.
|
artikel
|
| 106 |
Outcome of FLT3 ITD Mutated AML Patients Based on Different Treatment Strategies
|
Badar, Talha
|
|
2015
|
15 |
S |
p. S198-
1 p.
|
artikel
|
| 107 |
Outcomes of second allogeneic hematopoietic stem cell Transplantation (Allo-SCT) in patients with acute lymphoblastic leukemia (ALL)
|
Al Malki, Monzr M.
|
|
2015
|
15 |
S |
p. S175-
1 p.
|
artikel
|
| 108 |
Palmitic acid as an anti-multiple myeloma molecule was sorted out from lipid profiling by secondary ion mass spectrometry
|
Nagata, Yasuyuki
|
|
2015
|
15 |
S |
p. S238-
1 p.
|
artikel
|
| 109 |
Phase I/IIa trial of volasertib combined with decitabine in patients with acute myeloid leukemia (AML) ineligible for intensive therapy
|
Cortes, Jorge E.
|
|
2015
|
15 |
S |
p. S193-
1 p.
|
artikel
|
| 110 |
Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
|
DeAngelo, Daniel J.
|
|
2015
|
15 |
S |
p. S194-
1 p.
|
artikel
|
| 111 |
Phase I study of volasertib combined with azacitidine in patients with previously untreated, high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) ineligible for high-intensity therapy
|
Platzbecker, Uwe
|
|
2015
|
15 |
S |
p. S233-
1 p.
|
artikel
|
| 112 |
Practical Guide to Management of Lenalidomide-Related Rash in Patients with MDS
|
Tinsley, Sara
|
|
2015
|
15 |
S |
p. S233-S234
2 p.
|
artikel
|
| 113 |
Practical Management of Lenalidomide-Related Rash
|
Tinsley, Sara M.
|
|
2015
|
15 |
S |
p. S64-S69
6 p.
|
artikel
|
| 114 |
Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
|
Choi, Michael Y.
|
|
2015
|
15 |
S |
p. S167-S169
3 p.
|
artikel
|
| 115 |
Pretreatment FMS like Tyrosine kinase-3 Internal Tandem duplication (FLT3-ITD) Mutant Allele Burden Does Not Predict Response to the Combination of Sorafenib and Azacytidine in Patients with Relapsed or High Risk Elderly Untreated Acute Myeloid Leukemia
|
George, Binsah
|
|
2015
|
15 |
S |
p. S196-S197
2 p.
|
artikel
|
| 116 |
Proceedings of the Annual Meeting of the Society of Hematologic Oncology, 2014
|
|
|
2015
|
15 |
S |
p. S1-
1 p.
|
artikel
|
| 117 |
Prognosis and Molecular Monitoring in Chronic Myeloid Leukemia
|
Egan, Daniel
|
|
2015
|
15 |
S |
p. S109-S113
5 p.
|
artikel
|
| 118 |
Prognostic Factors in Patients with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody
|
Sasaki, Koji
|
|
2015
|
15 |
S |
p. S172-S173
2 p.
|
artikel
|
| 119 |
Prognostic model based on JAK2, CALR and MPL mutation status and age predicts the survival outcome of patients with primary myelofibrosis
|
Rozovski, Uri
|
|
2015
|
15 |
S |
p. S235-
1 p.
|
artikel
|
| 120 |
Prognostic Significance of Copy Number Alterations in B-lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled in Risk-adapted Protocols from the PETHEMA Group
|
Ribera, Jordi
|
|
2015
|
15 |
S |
p. S173-S174
2 p.
|
artikel
|
| 121 |
Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program
|
Liu, Zhiyu
|
|
2015
|
15 |
S |
p. S216-
1 p.
|
artikel
|
| 122 |
Real-world treatment patterns in first line and relapsed Chronic Lymphocytic Leukemia (CLL)
|
Feinberg, Bruce
|
|
2015
|
15 |
S |
p. S204-S205
2 p.
|
artikel
|
| 123 |
Reduced Intensity Conditioned (RIC), HLA-haploidentical BMT in AML
|
Showel, Margaret M.
|
|
2015
|
15 |
S |
p. S190-
1 p.
|
artikel
|
| 124 |
Relapsed Acute Myeloid Leukemia: Need for Innovative Treatment Strategies to Improve Outcome
|
Badar, Talha
|
|
2015
|
15 |
S |
p. S104-S108
5 p.
|
artikel
|
| 125 |
Relationship between blood cultures and antibiotic changes in neutropenic fever
|
Yezefski, Todd
|
|
2015
|
15 |
S |
p. S198-
1 p.
|
artikel
|
| 126 |
Resveratrol Increases CHD4 Gene Expression and Regulates Wnt Signaling in Chronic Myeloid Leukemia
|
Mutlu, Zeynep
|
|
2015
|
15 |
S |
p. S215-
1 p.
|
artikel
|
| 127 |
Retrospective Comparison of the Effectiveness of Various Treatment Modalities of Extragastric MALT Lymphoma: A single center analysis
|
Wöhrer, Stefan
|
|
2015
|
15 |
S |
p. S219-
1 p.
|
artikel
|
| 128 |
Retrospective outcomes in patients with BCR-ABL positive Acute Lymphoid Leukemia without Allogeneic stem cell transplantation at the Houston Methodist
|
Patel, Asmita
|
|
2015
|
15 |
S |
p. S176-
1 p.
|
artikel
|
| 129 |
Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome–Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus
|
Chamseddine, Ali N.
|
|
2015
|
15 |
S |
p. S129-S140
12 p.
|
artikel
|
| 130 |
Reversible mobilization of lymphoma cells to the peripheral blood by Plerixafor
|
El Dika, Imane
|
|
2015
|
15 |
S |
p. S225-
1 p.
|
artikel
|
| 131 |
Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia
|
Pagel, John M.
|
|
2015
|
15 |
S |
p. S201-S202
2 p.
|
artikel
|
| 132 |
Second Myeloid and Lymphoid Malignancies in patients with Chronic Lymphocytic Leukemia
|
Sandoval, Jose
|
|
2015
|
15 |
S |
p. S207-S208
2 p.
|
artikel
|
| 133 |
Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience
|
Chavez, Julio C.
|
|
2015
|
15 |
S |
p. S14-S18
5 p.
|
artikel
|
| 134 |
Standard and High Sensitivity Molecular Analysis in Chronic Myeloid Leukemia Patients Candidate to Discontinuation of Tyrosine Kinase Inhibitors
|
Irene, Dogliotti
|
|
2015
|
15 |
S |
p. S214-
1 p.
|
artikel
|
| 135 |
Successful treatment of hydroxyurea-associated chronic leg ulcers and squamous cell carcinoma in a patient with essential thrombocythemia
|
Antar, Ahmad
|
|
2015
|
15 |
S |
p. S237-
1 p.
|
artikel
|
| 136 |
Table of Contents
|
|
|
2015
|
15 |
S |
p. A6-A9
nvt p.
|
artikel
|
| 137 |
Targeting p53 in CML Chronic Phase Leukemia Stem Cells
|
Peterson, Luke F.
|
|
2015
|
15 |
S |
p. S215-
1 p.
|
artikel
|
| 138 |
The Impact of NOTCH1 in the Prognosis of Chronic Lymphocytic Leukemia (CLL)
|
Chaudhury, Ateefa
|
|
2015
|
15 |
S |
p. S205-S206
2 p.
|
artikel
|
| 139 |
The prognostic significance of additional cytogenetic abnormalities in adults with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplant
|
Aldoss, Ibrahim
|
|
2015
|
15 |
S |
p. S174-S175
2 p.
|
artikel
|
| 140 |
The prognostic value of molecular bone marrow involvement in aggressive lymphoma patients
|
Goldschmidt, Neta
|
|
2015
|
15 |
S |
p. S224-S225
2 p.
|
artikel
|
| 141 |
Therapeutic activity of a bi-specific T cell engaging, TCR-mimic monoclonal antibody to WT1 against human leukemias and cancers in mouse models
|
Pankov, Dmitry
|
|
2015
|
15 |
S |
p. S178-
1 p.
|
artikel
|
| 142 |
The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients
|
Gonsalves, Wilson I.
|
|
2015
|
15 |
S |
p. S239-
1 p.
|
artikel
|
| 143 |
The role of pregnancy induced hormonal milieu in lymphoma progression
|
Horowitz, Netanel A.
|
|
2015
|
15 |
S |
p. S230-
1 p.
|
artikel
|
| 144 |
To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors
|
Menghrajani, Kamal
|
|
2015
|
15 |
S |
p. S236-
1 p.
|
artikel
|
| 145 |
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization
|
Sallman, David A.
|
|
2015
|
15 |
S |
p. S50-S55
6 p.
|
artikel
|
| 146 |
Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas
|
Abramson, Jeremy S.
|
|
2015
|
15 |
S |
p. S141-S146
6 p.
|
artikel
|
| 147 |
Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
|
Komrokji, Rami S.
|
|
2015
|
15 |
S |
p. S56-S59
4 p.
|
artikel
|
| 148 |
Tumor Suppressor Role for B55 alpha PP2A Isoform in AML
|
Ruvolo, Peter P.
|
|
2015
|
15 |
S |
p. S180-S181
2 p.
|
artikel
|
| 149 |
U2AF1 mutation in de novo myelodysplastic syndromes (MDS) and its genetic evolution profile of secondary acute myeloid leukemia (sAML): a comparative analysis of 68 paired matched samples
|
Ou, Che-Wei
|
|
2015
|
15 |
S |
p. S186-
1 p.
|
artikel
|
| 150 |
Underexpression of EZH2 in Myelodysplastic Syndromes
|
Wei, Yue
|
|
2015
|
15 |
S |
p. S231-
1 p.
|
artikel
|
| 151 |
Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response
|
Moustafa, Muhamad Alhaj
|
|
2015
|
15 |
S |
p. S238-
1 p.
|
artikel
|
| 152 |
Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome
|
Komrokji, Rami
|
|
2015
|
15 |
S |
p. S60-S63
4 p.
|
artikel
|
| 153 |
Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes (MDS)
|
Ramadan, Hanadi
|
|
2015
|
15 |
S |
p. S232-S233
2 p.
|
artikel
|
| 154 |
Very High Dose Cytarabine as Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia in the Setting of Intensified Anthracycline Induction and Post Stem-Cell Transplantation
|
Itchaki, Gilad
|
|
2015
|
15 |
S |
p. S184-
1 p.
|
artikel
|
| 155 |
What qualifies as “true” salvage therapy in acute myeloid leukemia?: CR rates with second salvage depending on type of first salvage
|
Araki, Daisuke
|
|
2015
|
15 |
S |
p. S191-S192
2 p.
|
artikel
|
| 156 |
Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
|
Oran, Betul
|
|
2015
|
15 |
S |
p. S43-S49
7 p.
|
artikel
|
Tijdschrift beschrijving